Heart Pump Operated by Electric Cable Routed Through Mind


Left ventricular assist devices (LVADs), popularized including by Dick Cheney, have grown to be somewhat common previously couple of years. They augment the cardiac output, and in some cases they’ve considerably extended the lifespans of heart failure patients.

Managing LVADs could be a challenge, having a particular emphasis put on maintaining your area in which the cord comes from the body pristinely clean. Typically, the cord is undergone your skin around the abdomen, but keeping that area clean might be difficult if it is vulnerable to being wet or soiled. In the Osaka College Hospital in Japan, clinicians faced just this type of problem.

A heart failure patient with finish-stage kidney disease wanted with an LVAD implanted. Japan’s national health system doesn’t offer LVADs to patients who’ve another serious condition, for example kidney failure. Yet, the individual ended up getting an exemption in the situation, possibly since the doctors desired to try routing the cable therefore it comes from the mind. It was since the patient loves to absorb the tub, and raising the cable’s exit port over the tube was preferred.

The surgery effectively routed the ability cable with the neck and from the mind, roughly where bone performing assistive hearing devices are usually connected. The LVAD continues to be energized and also the patient securely discharged to visit home and soak away within the tub.

Osaka University…

Editors

At Medgadget, we set of the most recent medical technology news, interview leaders within the field, and file dispatches from medical occasions from around the globe.

Tempus unveils a standalone tool for structuring clinical data at scale

technology, tech, IT, health IT, information technology

So why do some patients react to immuno-oncology drugs when others don’t?

It’s one of several million-dollar questions in medicine that confound companies, researchers, and clinicians alike. And also the really frustrating part? We all know where most of the solutions lie. They’re held in electronic health records (EHRs) and siloed by disparate health systems.

Chicago, Illinois-based Tempus is trying to extract that information at scale. The 2-year-old company lately started offering an operating-system, dubbed Tempus O, made to structure, cleanse, and annotate clinical data.

Tempus O is a a part of an finish-to-finish service which includes full DNA and RNA sequencing at its CAP/CLIA-certified labs. However, the organization found a lot of its clients wanted to pay attention to the information organization component, Chief executive officer Eric Lefkofsky stated, to harness the phenotypic, therapeutic, and outcome and response data.

“People wish to structure this data clinically simply because they think that getting that data in their fingertips will assist them have better choose to their sufferers,” Lefkofsky stated via phone. “And people wish to structure that data for research because, clearly, it’s vital to allow them to understand: Exist particular characteristics leading many people to possess outsized positive or outsized negative responses to the therapeutic?”

It’s harder of computer sounds.

Some medical records happen to be digitized recently, they’re not quite “user-friendly” sources. These were created for medical billing, in the end. Many of the important information is tangled up in free text — individuals hastily written progress notes.

Tempus O taps into some sophisticated workflow tools, including optical character recognition and natural language processing, which extract meaning out of this text. Individuals notes may then be compared and arranged inside a bigger dataset, together with insights from research databases, images, and scans. Lefkofsky stated the organization has additionally developed a group of abstractors that may by hand input data when needed and evaluate the finished work.

Obviously, all this is performed at scale, to power real insights.

“To provide you with some perspective with that, we predict to structure around 400,000-patients price of data within the next 12 several weeks,” Lefkofsky stated.

That’s almost one-quarter from the 1.seven million Americans likely to be identified as having cancer in 2017.

Unsurprisingly, there’s big interest in this kind of software.

In September, Tempus closed a $70 million Series C round co-brought by New Enterprise Associates (NEA) and Revolution Growth. That cash injection introduced the startup’s total funding to $130 million. (Lefkofsky, a serial entrepreneur, has additionally invested a lot of personal money).

It’s only some of the player hanging around. Palo Alto, California-based Syapse closed a $$ 30 million Series D round in November, for as many as $71 million elevated.

While Syapse also activly works to bring fragmented clinical, molecular, treatment, and health outcomes data together, it is centered on the program component. Instead of carry out the sequencing, it’s collaborations with assorted labs.

Inside a This summer interview with MedCity News, Lefkofsky stated a part of his company’s edge continues to be the opportunity to do all of it, to simplify the connection using the client.

Nevertheless the molecular information is generated, both Syapse and Tempus concurs the two data sources have to be examined together.

“As a business, we’re most thinking about the mixture of both clinical data and also the molecular data,” Lefkofsky stated. “When you will find the molecular data you may also answer the ultimate goal question, that is ‘why.’ How come these patients responding well? How come these patients not responding well? For cancers, that’s a molecular question frequently.”

Photo: coffeekai, Getty Images

Computer Simulation Aims to know Arrhythmia-Caused Sudden Cardiac Dying


Sudden cardiac dying caused by an arrhythmia is really a rare and hard to review disorder. Now researchers at Johns Hopkins College allow us a pc type of the center particularly mimicking what goes on into it just before and through sudden cardiac dying. The biomolecular simulation has already been pointing to drug targets that needs to be considered a possible safety measure for that serious arrhythmias that finish up causing sudden cardiac dying.

“For the very first time, we’ve think of a way of relating how distressed molecular mechanisms in cardiovascular disease determine the prospect of arrhythmias in cardiac tissue,” said Raimond L. Winslow, professor of Biomedical Engineering at Hopkins and senior author from the study. “The need for this really is that people are now able to evaluate exactly how these dysfunctions drive and influence the probability of arrhythmias. In other words, we’ve a means of identifying the most crucial controlling molecular factors connected using these arrhythmias.”

The simulation models the center around the general level, in general organ, and also on cellular and molecular levels. Ion channels that move calcium received particular focus of attention, because they appear to experience a huge role in setting the rhythm from the heart. Inside the simulation they demonstrated that cardiac cells overfilled with calcium, as happens frequently in cardiovascular disease patients, finish up releasing the calcium and along the way generating electrical signals. If an adequate amount of cells carrying this out produce a sufficiently strong signal simultaneously, it may be the trigger that starts an arrhythmia. This appears to become a clue of why sudden cardiac dying is very rare, as the likelihood of enough cells grouping together to make a sufficiently strong effect is small.

Study in PLOS Computational Biology: Estimating the odds of rare arrhythmic occasions in multiscale computational types of cardiac cells and tissue…

Via: Johns Hopkins…

Editors

At Medgadget, we set of the most recent medical technology news, interview leaders within the field, and file dispatches from medical occasions from around the globe.

Apprentice safeguards $2.5 million for augmented reality tool aimed toward biopharma manufacturing

Jersey City, Nj-based Apprentice is getting augmented reality towards the arena of pharma and biotech manufacturing.

The startup lately elevated $2.5 million to assist it pursue its goal. Charge investor was Silverton Partners, and Hemi Ventures also participated.

Inside a phone interview, Apprentice cofounder and Chief executive officer Angelo Stracquatanio stated the funding may be the company’s seed round.

Advertisement

“We view it like a positive sign the market is relocating the direction we’d always wished it might relocate,” he stated. “AR has been adopted in a commercial scale.”

Stracquatanio noted the money will be used to expand their development area, work on R&D and improve its core product.

Apprentice’s solution has three primary modules, which operate on smart glasses like Google Glass and Microsoft HoloLens.

The very first, known as Tandem, is aimed toward collaboration. When an worker needs the help of an issue expert, Tandem enables the happy couple to speak, even if they’re in various locations. While using tool, the remote expert can easily see exactly what the worker around the manufacturing floor sees and coach her or him with the issue.

Another area of the solution, Manuals, can serve as the startup’s process and workflow aid. It enables users to possess hands-free use of operating procedures along with other tasks.

Gauge may be the third bit of the puzzle and is dependant on data collection and safety at work. Instead of spending exorbitant intervals recording information, operators may use the module to collect lab and manufacturing data while performing another task.

The best goal would be to leverage augmented reality to enhance efficiency and safety in laboratory and manufacturing environments.

“We were so inspired by Apprentice’s desire for using the most advanced technology to provide real solutions for labs and sophisticated manufacturers,” Mike Dodd, partner at Silverton Partners, stated inside a statement. “They are management in making use of augmented reality to supply direct client benefits because of the users’ enhanced operational experience.”

Stracquatanio stated Apprentice’s revenue model has two phases.

The very first is an airplane pilot phase, where the organization provides from the program towards the smart glasses to some client. The Jersey City startup also provides the customer with training and support through the duration of the pilot, which generally lasts between one and three several weeks.

“If you place it and end up forgetting it, it is not fruitful on their behalf or us,” Stracquatanio stated. “We address it like a collaborative effort.”

Following the early on, Apprentice relies on a software-as-a-service model with different per device or per user basis.

Photo: abluecup, Getty Images

Scientists Create Living 3D Printer Made from Live Bacteria


Fishing rod-formed bacteria produce cellulose, recognizable like a thread-like structures.

Researchers at ETH Zurich in Europe have reported in journal Science Advances on a means of 3D printing materials infused with live bacteria. The event can lead to devices for example implantable bloodstream filters and microbial factories that leave biomolecules for drugs along with other therapies. An array of other applications might find use out of this technology.

They created a hydrogel ink within which microbial cultures can be put. The hydrogel, made from pyrogenic silica and hyaluronic acidity, that has lengthy chain molecules, provides strength towards the objects to become printed. Culture medium to give the bacteria can also be put into this mixture and also the printing process is gentle, allowing the bacteria to stay vibrant and also the medium to help keep feeding it. Furthermore, the present setup can print using four different inks simultaneously, allowing as much as four different microbial cultures to trouble just one object.

They produced objects out of Pseudomonas putida, a bacteria that may decompose phenol, a typical chemical consequence, and Acetobacter xylinum, a bacteria that poops out nanocellulose. The passed nanocellulose has possibility of use within treating wounds, potentially resulting in dressings filled with live bacteria constantly trying to heal wounds.

Here’s a fast video from ETH Zurich demonstrating a lot of it and also the printing process:

Study in Science Advances: 3D printing of bacteria into functional complex materials…

Via: ETH Zurich…

Editors

At Medgadget, we set of the most recent medical technology news, interview leaders within the field, and file dispatches from medical occasions from around the globe.

The Food and drug administration weighs in on 3D printing, offering assistance with pathways for manufacturers

3D printed brain model for surgical simulation by Stratasys Direct Manufacturing.

The Food and drug administration just released new guidance for 3D-printed devices, trying to clarify the path manufacturers are required to follow to have their products approved. This is actually the FDA’s latest make an effort to keep pace having a fast-moving technology. A couple of days ago, the company shared their emerging method of molecular diagnostics.

But 3D printing, or additive manufacturing in agency nomenclature, offers its very own unique regulatory challenges. We’ve got the technology has lengthy been a benefit within the design process, driving rapid, iterative prototyping and evaluation. However with these approaches getting into the clinic, the company felt the necessity to take further action.

Advertisement

“The Food and drug administration is worried where there’s 3D technology inside a tool and being directly implanted in patients,” stated Patrick Kullmann, founder and lead strategist at CG3 Talking to and president and COO at Medovex, inside a phone interview. “Once you begin a 3D printing process to have an implantable heart valve, or implantable knee or hip, it’s another story.”

Food and drug administration Commissioner Scott Gottlieb noted inside a statement associated the guidance that 3D printing can manufacture drugs, fabricate skin grafts for burn victims as well as provide substitute organs. The guidance seeks to assist manufacturers better comprehend the agency’s needs for device design, function, durability and quality because these applications move ahead. But it is also targeted at clinicians, who’re developing their very own devices.

“The Food and drug administration says that: If you are altering devices or creating devices inside a hospital to be used inside a patient, this can be a totally new frontier, and we’re walking as much as provide some initial guidance in regards to what we’re searching for in such cases,” stated Kullmann.

Fraxel treatments can dramatically accelerate the merchandise development process, forcing the Food and drug administration to maintain. Gottlieb’s statement notes the company has generated its very own 3D-printing abilities within the Center for Drug Evaluation and Research’s Emerging Technology Program.

Though 3D printing has unique abilities to personalize care, for example supplying custom-fitted memory foam implants, it’s not without precedent, giving the Food and drug administration something to construct on.

“Over the last 10 years, we’ve produced aortic stent grafting – an endograft which has compressible metal mesh that can take pressure from the artery,” stated Kullmann. “These are custom-designed for each patient, a lot like obtaining a custom set of footwear.”

The Food and drug administration recognizes 3D printing is really a moving target and it is acting accordingly. The company can also be taking another take a look at bioprinting to enhance its lately released regenerative medicine framework. Gottlieb’s statement also notes that, like 3D printing itself, regulation is definitely an iterative process.

“But this technical guidance – categorized like a leap-frog guidance since it helps bridge where we’re today with innovations of tomorrow – is just meant to supply the FDA’s initial ideas with an emerging technology using the knowning that our recommendations will probably evolve because the technology develops in unpredicted ways.”

Photo: Stratasys Direct Manufacturing

College of Minnesota Researchers Create a Better 3D-Printed Organ Model


3D-printed organ designs include proven lots of promise in medicine by supplying doctors having a tangible representation of the organ being studied. While these models are wonderful at mimicking the dimensions and exterior appearance of the biological counterparts, otherwise they’re typically not so helpful.

Researchers in the College of Minnesota have finally developed 3D-printed organ mixers are a little more functional. Furthermore they precisely replicate the look of a body organ, they also precisely mimic both exterior and internal physiological structures, mechanical qualities, and feel. It was accomplished by developing customized silicone-based inks that precisely match the mechanical qualities from the biological tissues being mimicked after which fabricating the organ models on custom-built 3D printers.

They also attached flexible, 3D-printed sensors towards the organ mixers measure pressure and pressure. This enables researchers and clinicians to see the results of compression tests and the use of sutures along with other surgical tools around the model, that could better train surgeons about how much pressure they are able to apply with no damage to tissues.

Researchers will also be investigating how you can print with multiple inks to produce more complicated organ models. Such models may even mimic the existence of a tumor or deformity, so surgeons can test different techniques for removing tumors or correcting physiological complications.

Check out a short video explaining the organ models:

Study in Advanced Materials Technologies: 3D Printed Organ Models with Physical Qualities of Tissue and Integrated Sensors…

Via: College of Minnesota…

(hat tip: MDO)

Scott Jung

Scott Jung (@scottjung) is really a Plastic Valley-based health and medical technology journalist and advocate. He is a guest cause of Intel’s iQ e-magazine and Rock Health’s corporate blog and it has provided live, on-site coverage from the Worldwide CES and Digital Health Summit, TEDMED, and Stanford Medicine X conference for Medgadget. Most lately, he’s been appearing on TWiT.tv’s The Brand New Screen Savers like a semi-regular health and medical technology correspondent. Scott holds a b -.Utes. degree in Biomedical Engineering in the College of Los Angeles. Scott is definitely searching for the following big factor in medical technology and digital health. Thinking about helping him transform lives? Make contact with him at http://scottjung.internet

Which pharma information mill probably the most transparent with medical trial data?

New research co-created by the founding father of Bioethics Worldwide, a non-profit focused on ethics and transparency within the pharmaceutical sector, determined that Manley and Manley and Sanofi/Genzyme earned top marks and were far above other drug developers at discussing medical trial data. The research was printed in BMJ Open —an online, open access journal, which publishes scientific research all disciplines and therapeutic areas.

The research centered on the 19 drugs approved in 2014, so pharma companies that didn’t get drugs approved that year, Pfizer and GlaxoSmithKline, weren’t incorporated within the Good Pharma Scorecard.

The research found that the median proportion of trials conducted in patients with openly available results rose from 87 percent this year once the first such study ended to 96 percent in 2014.

Advertisement

Other notable findings were that 10 of 19 drugs (53 %) had a minumum of one undisclosed trial conducted in patients. Six drugs (32 percent) had a minumum of one undisclosed phase II or III trial. A minimum of 2,864 patients took part in trials with undisclosed results.

Jennifer Miller, a bioethicist at New You are able to College and founding father of Bioethics Worldwide stated the following edition of clinical data discussing league tables includes patient-level data discussing — data which scientific organizations have pressed for inclusion, based on the Researcher. It’ll also explore reporting transparency for trials connected with unapproved drugs that have been only lately needed to become reported underneath the FDAAA.

A table in the study printed in BMJ Open:

Companies’ overall medical trial transparency rankings for drugs approved in 2014*

Rank Company Transparency score (%)
#1 Manley & Manley/Janssen 100
#1 Sanofi/Genzyme 100
#3 Abbvie 96
#4 Celgene 95
#5 Merck 93
#6 AstraZeneca 91
#7 Roche 90
#8 Novartis 88
#9 Gilead 73
#10 Allergan 63
#11 Valeant 50
Median 91

Photo: Natali_Mis, Getty Images

Accurate Glucose Monitor Integrated In the Smartphone Situation


While smartphones happen to be gaining all sorts of features for example Gps navigation, barometry, and depth perception, diabetics are most likely wondering why glucometers continue to be stand-alone devices. Well, this can be altering too, as researchers at College of California North Park allow us a glucose meter that’s included in a smartphone situation, which may eventually become a real a part of a production phone.

The sensor from the so-known as GPhone is multiple-use, however it does require single-use enzyme-carbon composite pellets that contains glucose oxidase which are placed on top of the sensor before a small amount of bloodstream is added. The pellets come in the stylus that dispenses them individually. They’re magnetic, and thus keep to the metal bare strip sensor from the new glucometer. The sensor, along with an electronics package within the phone’s situation, measures the electrical signal generated through the result of the glucose within the bloodstream using the pellets, wirelessly transmitting the end result towards the smartphone. After that an application can manage the readings, allow you to share them, and do the rest of the things today’s diabetes apps do. It has all been accomplished inside a working proof-of-concept device model, but you will see challenges to lessen the price of the person pellets and possibly enhance their usability.

The introduction of the GPhone technology could be a pretty problem for diabetics, as loosing glucometer could be a considerable health risks and schlepping it around along with you inside a purse or pocket isn’t necessarily a perfect situation.

Study in journal Biosensors and Bioelectronics: Re-functional electrochemical glucose sensors built-into a smartphone platform…

Via: College of California San Diego…

Editors

At Medgadget, we set of the most recent medical technology news, interview leaders within the field, and file dispatches from medical occasions from around the globe.

Tissue Analytics expands from New England, establishes office in Might

Tissue Analytics wound monitoring platform

Wound monitoring technology startup Tissue Analytics has built an eight person office in Might, Kansas following its hire of former Cerner staffer there who setup work within his new role as v . p . of sales, based on a tale through the Might Business Journal.  It marks an expansion for the organization which formerly was resides in one office in Baltimore.

Captured Tissue Analytics became a member of Cerner’s Open Development Experience, which provides third-party developers the opportunity to build applications that can interface using its electronic health record systems. Tissue Analytics Chief executive officer Kevin Keenahan told the company journal that the opportunity to integrate straight into Cerner’s Electronic health record may help his business streamline installation in days.

In October, Tate Gilchrist, senior business developer of open platform services for Cerner, told the company journal it had about 22 commercial application developers partnering using its systems.

Captured Tissue Analytics inked an offer with Intermountain Healthcare in Salt Lake City to integrate the startups’s wound monitoring technology, moving that adopted a 16 week pilot of Tissue Analytics technology this past year.

Tissue Analytics has a smartphone application, which clinicians use to snap a photograph of the wound, after which, through some algorithms, data concerning the wound’s shape and color are recorded, kept in the cloud, and readily available for nurses and doctors to gain access to. Its approach is made to make workflows simpler and much more intuitive and is made to rival medtech titans such as Philips.

MedCity ENGAGE, October 23-24 in North Park, concentrates on the most recent strategies and innovations to boost patient engagement, care delivery and company wellness. Use code MCNTAG in order to save $50.